ATE532774T1 - Benzoxazole und oxazolopyridine als janus- kinasehemmer - Google Patents

Benzoxazole und oxazolopyridine als janus- kinasehemmer

Info

Publication number
ATE532774T1
ATE532774T1 AT07802300T AT07802300T ATE532774T1 AT E532774 T1 ATE532774 T1 AT E532774T1 AT 07802300 T AT07802300 T AT 07802300T AT 07802300 T AT07802300 T AT 07802300T AT E532774 T1 ATE532774 T1 AT E532774T1
Authority
AT
Austria
Prior art keywords
oxazolopyridines
benzoxazoles
kinase inhibitors
janus kinase
janus
Prior art date
Application number
AT07802300T
Other languages
German (de)
English (en)
Inventor
Marc Gerspacher
Pascal Furet
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532774(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE532774T1 publication Critical patent/ATE532774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07802300T 2006-09-15 2007-09-13 Benzoxazole und oxazolopyridine als janus- kinasehemmer ATE532774T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
PCT/EP2007/007983 WO2008031594A1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Publications (1)

Publication Number Publication Date
ATE532774T1 true ATE532774T1 (de) 2011-11-15

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07802300T ATE532774T1 (de) 2006-09-15 2007-09-13 Benzoxazole und oxazolopyridine als janus- kinasehemmer

Country Status (30)

Country Link
US (1) US8629168B2 (enExample)
EP (2) EP1900729A1 (enExample)
JP (1) JP5325105B2 (enExample)
KR (1) KR20090064389A (enExample)
CN (1) CN101516860B (enExample)
AR (1) AR062786A1 (enExample)
AT (1) ATE532774T1 (enExample)
AU (1) AU2007296916B2 (enExample)
BR (1) BRPI0716841A2 (enExample)
CA (1) CA2660987A1 (enExample)
CL (1) CL2007002669A1 (enExample)
CO (1) CO6150142A2 (enExample)
CR (1) CR10639A (enExample)
EA (1) EA200900388A1 (enExample)
ES (1) ES2377148T3 (enExample)
GT (1) GT200900056A (enExample)
IL (1) IL196860A0 (enExample)
MA (1) MA30723B1 (enExample)
MX (1) MX2009002812A (enExample)
NO (1) NO20091469L (enExample)
PA (1) PA8748101A1 (enExample)
PE (1) PE20080842A1 (enExample)
PL (1) PL2066647T3 (enExample)
PT (1) PT2066647E (enExample)
SM (1) SMP200900023B (enExample)
TN (1) TN2009000070A1 (enExample)
TW (1) TW200819444A (enExample)
UY (1) UY30587A1 (enExample)
WO (1) WO2008031594A1 (enExample)
ZA (1) ZA200900477B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
MX2011000211A (es) * 2008-07-15 2011-03-03 Sanofi Aventis Oxazolopirimidinas como agonistas del receptor edg-1.
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン－３－カルボキシアミド誘導体
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
TWI485153B (zh) * 2010-01-13 2015-05-21 Sanofi Aventis ２，５，７－經取代唑并嘧啶衍生物
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
KR20180035894A (ko) 2015-08-03 2018-04-06 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022251597A1 (en) 2021-05-28 2022-12-01 Verge Analytics, Inc. Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
CA2620127A1 (en) * 2005-09-02 2007-03-08 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
EP1900729A1 (en) 2008-03-19
AR062786A1 (es) 2008-12-03
CA2660987A1 (en) 2008-03-20
AU2007296916A1 (en) 2008-03-20
KR20090064389A (ko) 2009-06-18
EA200900388A1 (ru) 2009-08-28
JP5325105B2 (ja) 2013-10-23
US20100009978A1 (en) 2010-01-14
TW200819444A (en) 2008-05-01
WO2008031594A1 (en) 2008-03-20
CN101516860A (zh) 2009-08-26
PL2066647T3 (pl) 2012-04-30
SMAP200900023A (it) 2009-05-11
ES2377148T3 (es) 2012-03-22
GT200900056A (es) 2011-11-08
NO20091469L (no) 2009-04-15
JP2010503629A (ja) 2010-02-04
BRPI0716841A2 (pt) 2013-10-01
AU2007296916B2 (en) 2011-10-06
PE20080842A1 (es) 2008-08-11
EP2066647B1 (en) 2011-11-09
EP2066647A1 (en) 2009-06-10
IL196860A0 (en) 2009-11-18
SMP200900023B (it) 2009-07-14
CL2007002669A1 (es) 2008-05-09
TN2009000070A1 (en) 2010-08-19
PT2066647E (pt) 2012-01-17
PA8748101A1 (es) 2009-08-26
CN101516860B (zh) 2012-06-27
CR10639A (es) 2009-07-03
MX2009002812A (es) 2009-03-31
MA30723B1 (fr) 2009-09-01
ZA200900477B (en) 2010-01-27
UY30587A1 (es) 2008-05-02
CO6150142A2 (es) 2010-04-20
US8629168B2 (en) 2014-01-14

Similar Documents

Publication Publication Date Title
ATE532774T1 (de) Benzoxazole und oxazolopyridine als janus- kinasehemmer
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
EP2097538A4 (en) TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
EP2083864A4 (en) ANTAGONISTS OF PCSK9
EP2083859A4 (en) PCSK9 ANTAGONISTS
EP2083860A4 (en) PCSK9 ANTAGONISTS
SMAP200800063A (it) Composti benzazolici e benzotiazolici-6-0-sostituiti e metodi di inibizione del segnale cfs-1r
BRPI0821285A2 (pt) derivados de benzotiazol e benzoxazol e métodos de uso
ATE525374T1 (de) Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
EP2041549A4 (en) MEASURING APPARATUS, METHOD AND COMPUTER PROGRAM
DE602007000700D1 (de) Laser-Materialbearbeitungsvorrichtung
PT1954684E (pt) Composto e composição farmacêutica de oxazol
ATE517097T1 (de) Thiazol- und oxazolsubstituierte arylamide
DK3399667T3 (da) Forhindring af selvinduceret interferens i anordning med dobbelt radio
DE102006051625A8 (de) Kombinationstherapie substituierter Oxazolidinone
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
PL1979099T3 (pl) Urządzenie do rozdrabniania części dowolnego rodzaju
EP2124563A4 (en) Benzimidazole TRPV1 INHIBITORS
ATE495153T1 (de) Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
FI20060503A0 (fi) Jakelulaite
FI20065775L (fi) Rikotuslaitteen työkalun laakerointi
EP2069390A4 (en) OPSIN STABILIZING COMPOUNDS AND METHODS OF USE
DE602007000308D1 (de) Schleifverfahren und Schleifmaschine